Goldman Sachs Maintains Buy on HCA Healthcare, Lowers Price Target to $485
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
Goldman Sachs analyst Scott Fidel maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $558 to $485.
Goldman Sachs analyst Scott Fidel maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $558 to $485.